Article Sidebar

Published: 2026-08-14
Abstract Views: 0
DOI: https://doi.org/10.52163/yhc.v67iCD12.6173
Issue
Tập 67 Số CĐ12- HNKH Bệnh viện Ung bướu Nghệ An
Section
Articles
How to Cite
Trọng, N. T., Anh, N. T. V., Hoa, N. T. Q., Hoa, N. T. Q., Nga, N. T., & Hòa, H. K. (2026). TREATMENT OUTCOMES OF DEFINITIVE CONCURRENT CHEMORADIOTHERAPY FOR STAGE II-IVA HYPOPHARYNGEAL CANCER AT NGHE AN ONCOLOGY HOSPITAL. Vietnam Journal of Community Medicine, 67(CD12). https://doi.org/10.52163/yhc.v67iCD12.6173

TREATMENT OUTCOMES OF DEFINITIVE CONCURRENT CHEMORADIOTHERAPY FOR STAGE II-IVA HYPOPHARYNGEAL CANCER AT NGHE AN ONCOLOGY HOSPITAL

Nguyen The Trong1, Nguyen Thi Van Anh1, Nguyen Thi Quynh Hoa1, Nguyen Thi Quynh Hoa1, Nguyen Thi Nga1, Ho Khanh Hoa1
1 Nghe An Oncology Hospital

Main Article Content

Abstract

Objective: To describe the clinical and paraclinical characteristics and evaluate the treatment outcomes of definitive concurrent chemoradiotherapy in patients with stage II-IVA hypopharyngeal cancer.


Subjects and methods: A retrospective descriptive study with longitudinal follow-up was conducted on 73 patients with stage II-IVA hypopharyngeal cancer who underwent definitive concurrent chemoradiotherapy at Nghe An Oncology Hospital from August 2020 to August 2025.


Results: The mean age was 61.3 ± 6.9 years. The most common presenting symptom was dysphagia (76.7%). The primary tumor was most frequently located in the pyriform sinus (63%), and squamous cell carcinoma was the predominant histopathological type (97.3%). Stage IVA accounted for 67.1% of cases. The objective response rate was 94.5%. The mean overall survival was 35.9 ± 3.4 months, with overall survival rates of 65%, 47%, and 40% at 12, 24, and 36 months, respectively. Treatment interruption was significantly associated with poorer overall survival (p < 0.05).


Conclusion: Definitive concurrent chemoradiotherapy is an effective treatment for patients with stage II-IVA hypopharyngeal cancer, achieving a high objective response rate and favorable overall survival.

Article Details

Keywords

Hypopharyngeal cancer, concurrent chemoradiotherapy.

References

[1] Cordunianu A.G.V et al. Hypopharyngeal cancer trends in a high-incidence region: a retrospective tertiary single center study. World J Clin Cases, 2023, 11 (24): 5666-5677. doi: 10.12998/wjcc.v11.i24.5666.
[2] Bae M.R, Roh J.L et al. 18F-FDG PET/CT versus CT/MR imaging for detection of neck lymph node metastasis in palpably node-negative oral cavity cancer. J Cancer Res Clin Oncol, 2020, 146 (1): 237-244. doi: 10.1007/s00432-019-03054-3.
[3] Bray F et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74 (3): 229-263. doi: 10.3322/caac.21834.
[4] Kanesaka T et al. Neoadjuvant chemotherapy and endoscopic resection for hypopharyngeal cancer. Clinical Gastroenterology and Hepatology, 2023, 21 (7): A43-A44. doi: 10.1016/j.cgh.2022.11.036.
[5] Lin T.Y et al. Survival analyses of different treatment modalities and clinical stage for hypopharyngeal carcinoma. Frontiers in Oncology, 2023, 13: 1109417. doi: 10.3389/fonc.2023.1109417.
[6] Mell L.K et al. Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial. Lancet Oncology, 2024, 25 (12): 1576-1588. doi: 10.1016/S1470-2045(24)00507-2.
[7] PDQ Adult Treatment Editorial Board. Hypopharyngeal Cancer Treatment (PDQ), 2024.
[8] Sad L.M, Khalil M.B et al. SIB-IMRT radiotherapy concomitant with cisplatin in locally advanced hypopharyngeal cancer: safety, feasibility. Onkologia i Radioterapia, 2021, 15 (4).